- Home
- PLD vs SNY Comparison
PLD vs SNY Comparison
Compare PLD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLD | SNY |
|---|---|---|
| Founded | 1983 | 1994 |
| Country | United States | France |
| Employees | 2802 | 74846 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0B | 104.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLD | SNY |
|---|---|---|
| Price | $140.39 | $42.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $140.78 | $58.00 |
| AVG Volume (30 Days) | ★ 2.8M | 2.5M |
| Earning Date | 04-16-2026 | 04-23-2026 |
| Dividend Yield | 3.08% | ★ 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.15 | $3.49 |
| Revenue Next Year | $6.12 | $6.10 |
| P/E Ratio | $39.25 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $103.41 | $42.28 |
| 52 Week High | $150.18 | $52.68 |
Technical Indicators
Market Signals| Indicator | PLD | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 39.55 |
| Support Level | $138.46 | N/A |
| Resistance Level | $145.67 | $48.76 |
| Average True Range (ATR) | 3.16 | 0.61 |
| MACD | -0.52 | -0.09 |
| Stochastic Oscillator | 23.31 | 10.34 |
Price Performance
Historical ComparisonAbout PLD Prologis Inc.
Prologis was formed by the 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.3 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party assets under management. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.